- PackSize
- 50ug/100ug
- Target
- CTLA-8
- Reactivity
- Human
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Humanized
- Isotype
- VH-VH'-VH
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 30 mM Histidine, pH5.8, 10% sucrose, 0.02% Tween80
- Purification Process
- Purified by Nickel column.
- Purity
- >95% purity as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1, ALB, Albumin
- Species
- --
- Gene ID-1
- Q16552 & Q96PD4 & P02768
- Uniprot
- --
- Background
- Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis.<br>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --